Drug clinics. Drug of the month. A new measles-rubella-mumps vaccine (Priorix)
Senterre, J.
Revue Medicale de Liege 54(2): 122-124
1999
ISSN/ISBN: 0370-629X PMID: 10221066 Document Number: 506306
A novel measles-mumps-rubella vaccine (Priorix) has been marketed by SmithKline Beecham. It contains live attenuated virus with measles and mumps strains slightly different from those present in MMR VAX (Pasteur Merieux MSD). The indications and contraindications are similar for both vaccines. Immunogenicity is also equivalent as well as general reactogenicity. By contrast local symptoms were reported significantly less frequently after Priorix.
Document emailed within 1 workday
Related Documents
da Silveira, C.Marcos.; Kmetzsch, C.Iris.; Mohrdieck, R.; Sperb, A.Fagundes.; Prevots, D.Rebecca. 2002: The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997 International Journal of Epidemiology 31(5): 978-982Trotter, A.C.; Stone, B.D.; Laszlo, D.J.; Georgitis, J.W. 1994: Measles, mumps, rubella vaccine administration in egg-sensitive children: systemic reactions during vaccine desensitization Annals of Allergy 72(1): 25-28
Lamabadusuriya, S.P. 2011: Measles, mumps, rubella (MMR) vaccine Ceylon Medical Journal 56(3): 135
Stück, B.; Stehr, K.; Bock, H.L. 2002: Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age Asian Pacific Journal of Allergy and Immunology 20(2): 113-120
Lang, S. 1998: Measles, mumps, rubella vaccine and allergy to egg American Family Physician 58(4): 863-864
Brunell, P.A.; Novelli, V.M.; Lipton, S.V.; Pollock, B. 1988: Combined vaccine against measles, mumps, rubella, and varicella Pediatrics 81(6): 779-784
Edwardes, M.; Baltzan, M. 2001: Measles, mumps, and rubella (MMR) vaccine and autism. Argument is too simplistic Bmj 323(7305): 163; Author Reply 164
Gatchalian, S.; Tabora, C.; Bermal, N.; Leboulleux, D.; Desauziers, E. 2004: Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old American Journal of Tropical Medicine and Hygiene 70(3): 273-277
Topal, B.; Kanra, G.; Ceyhan, M. 1991: Serological evaluation of 52 children immunized with the combined measles, mumps and rubella vaccine Turkish Journal of Pediatrics 33(1): 13-18
Kornbrot, B.; Levy, Y.; Garty, B.Z.; Danon, Y.L. 1990: Allergic reactions to measles, mumps and rubella vaccine in children with egg protein allergy Harefuah 119(7-8): 230-231
Vázquez Fernández, E.; López Rois, F.; Vázquez Carrete, J.A.; Gómez Tato, B.; Alvarez Ares, M. 1987: Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old Anales Espanoles de Pediatria 27(1): 27-31
Just, M.; Berger, R.; Glück, R.; Wegmann, A. 1985: Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella Schweizerische Medizinische Wochenschrift 115(48): 1727-1730
Trier, H.; Rønne, T. 1992: Duration of immunity and occurrence of secondary vaccine failure following vaccination against measles, mumps and rubella Ugeskrift for Laeger 154(29): 2008-2013
Gatchalian, S.; Cordero-Yap, L.; Lu-Fong, M.; Soriano, R.; Ludan, A.; Chitour, K.; Bock, H.L. 1999: A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age Southeast Asian Journal of Tropical Medicine and Public Health 30(3): 511-517
Cameron, N.A. 2012: When, and how, should we introduce a combination measles-mumps-rubella (MMR) vaccine into the national childhood expanded immunization programme in South Africa? Vaccine 30 Suppl. 3: C58-C60
Rotily, M.; Guagliardo, V.; Fontaine, D.; Garros, B.; Mayer, C.; Arrighi, J.; Woronoff, A.S.; Ledesert, B.; Lepec, R.; Chabaud, F.; Janvrin, M.P.; Baudier, F. 2001: Evaluation of measles, mumps and rubella vaccine coverage in 3 year old children in twelve French counties. Time-trends and related factors Revue d'Epidemiologie et de Sante Publique 49(4): 331-341
Heller, T. 2001: Ethical debate: Vaccination against mumps, measles, and rubella: is there a case for deepening the debate? how safe is MMR vaccine? Bmj 323(7317): 838-839; Discussion 840
He, H.; Chen, E.; Chen, H.; Wang, Z.; Li, Q.; Yan, R.; Guo, J.; Zhou, Y.; Pan, J.; Xie, S. 2014: Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in children Vaccine 32(31): 4001-4005
Luyckx, F.; Scheen, A.J. 1997: Drug clinics. Drug of the month. Legalon (silymarin) Revue medicale de Liege 52(12): 792-796
Rose, V.L. 1998: ACIP issues recommendations to eliminate measles, rubella and congenital rubella syndrome and to control mumps American Family Physician 58(7): 1682; 1685-1686